Roth Capital lowered the firm’s price target on CervoMed (CRVO) to $9 from $11 and keeps a Buy rating on the shares. The firm notes that Neflamapimod’s ability to improve CDR-SB with an acceptable safety profile continues to support is by recommendation. Roth adds that it expects Phase 3 study to begin in the second half of 2026, given an alignment with regulators has already been achieved. The firm states, however, that the key sticking point for stock appreciation is the ongoing financing overhang.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CRVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
- CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
- CervoMed presents neflamapimod MRI data
- CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia